Eyre TA, et al. - Researchers undertook this multi-centre retrospective analysis of 105 relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) patients who received venetoclax pre-National Health Service commissioning, to determine the efficacy of venetoclax monotherapy in these patients. Patients had median age of 67 years and median prior lines of 3 (range: 1–15). TP53 disruption was noted in 48%. At ≥2 lines, a Bruton Tyrosine Kinase inhibitor (BTKi) and no prior phosphoinositide 3-kinase inhibitor (Pi3Ki) were provided to 60%, a Pi3Ki and no prior BTKi was given to 25%, and there were 10% who received both. Outcomes support that among R/R CLL patients, venetoclax is active and is well tolerated in post ≥1 B cell receptor inhibitor (BCRi) setting. Venetoclax outcomes were identified to be influenced by reason(s) for stopping BCRi.